A detailed history of Criterion Capital Advisors, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Criterion Capital Advisors, LLC holds 2,201 shares of LLY stock, worth $1.69 Million. This represents 1.25% of its overall portfolio holdings.

Number of Shares
2,201
Previous 2,201 -0.0%
Holding current value
$1.69 Million
Previous $1.99 Billion -0.0%
% of portfolio
1.25%
Previous 1.25%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$724.87 - $909.04 $20,296 - $25,453
-28 Reduced 1.26%
2,201 $1.99 Billion
Q1 2024

Apr 17, 2024

SELL
$592.2 - $792.28 $40,269 - $53,875
-68 Reduced 2.96%
2,229 $1.73 Billion
Q4 2023

Jan 31, 2024

BUY
$525.19 - $619.13 $1.21 Million - $1.42 Million
2,297 New
2,297 $1.34 Billion

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $730B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Criterion Capital Advisors, LLC Portfolio

Follow Criterion Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Criterion Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Criterion Capital Advisors, LLC with notifications on news.